NEW YORK--(BUSINESS WIRE)--Pfizer Oncology will present nearly 30 abstracts highlighting research in new and established pathways, including inhibition of Hedgehog signaling (PF-04449913);1 dual inhibition of PI3K/mTOR (phosphatidylinositol 3-kinase/mammalian target of rapamycin)(PF-04691502);2 and cancer stem cell-based targets.3 Data from this research as well as data from studies involving investigational compounds, including crizotinib,4 an oral first-in-class compound that inhibits the anaplastic lymphoma kinase, or ALK, will be presented at the upcoming American Association for Cancer Research (AACR) 102nd Annual Meeting 2011 in Orlando, FL from April 2-6.
